


**Total Grants for research projects sponsored by non- government sources such as industry, corporate houses, international bodies, endowments, professional associations, endowment-Chairs in the Institution year-wise during the last five years.**


S. No.	Name of the project/ Clinical Trials/Endowment/Chairs	Name of the Principal Investigators /Co Investigator	Name of the Funding agency	Type (Government/ Non-Govt. etc.,)	Department of Principal Investigator	Year of Award
<b>2022-2023</b>						
1	Feasibility of a new diagnostic device to assess small intestinal dysbiosis in routine clinical setting	Prof. Uday C. Ghoshal	Atmo Biosciences Ltd.	Non-Govt.	Gastroenterology	2022-2023
2	A safety and Efficacy of Trans arterial Chemoembolization with Lipiodol ® in the treatment of inoperable Hepatocellular Carcinoma (HCC) in Indian	Dr. Rajnikant K. Yadav	SIRO Clinpharm Pvt. Ltd.	Non-Govt.	Radio diagnosis	2022-2023
3	A -2-year randomized, 3-arm, double-blind and non-inferiority study comparing the efficacy and safety of open label extension	Prof. Jayantee Kalita	Novartis Healthcare Pvt. Ltd.	Non-Govt.	Clinical Immunology	2022-2023

4	A multicenter, randomized, double, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy	Dr. Dharmendra Singh Bhadauria	Novartis Healthcare Pvt. Ltd.	Non-Govt.	Nephrology	2022-2023
5	A Prospective, Open Label, Multi-centered, Non-Randomized, Non-comparative Active Post-Marketing to rest the safety and efficacy of Diperoxochloric Acid (DPOCL) topical Solution in subjects with diabetic neuropathic ulcers of skin and subcutaneous tissue	Dr. Gyan Chand	Centaur Pharmaceuticals Pvt. Ltd.	Non-Govt.	Endocrine Surgery	2022-2023
6	A Randomized, Multi Center, Parallel, Open Label Study Assessing Ckinical and Functional Outcomes After Anterior Cruciate Ligament (ACL) Reconstruction Procedure Using Suspensory Tibal Fixation with Open and closed Peek Button	Dr. Pulak Sharma	Healthium Medtech Ltd.	Non-Govt.	Orthopedics, ATC	2022-2023
7	A Prospective, randomized, two-arm, parallel, placebo-controlled, multicenter, superiority, phase II clinical trial to evaluate the immunogenicity and safety of recombinant Hepatitis E Vaccine	Prof. Amit Goel	Zyus Lifesciences Ltd.	Non-Govt.	Hepatology	2022-2023

  
**Lt Col Varun Bajpai VSM**  
 Executive Registrar  
 SGPIGMS, Lucknow

8	A randomized , double-blind, double dummy, parallel group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open label remibrutinib	Prof. Jayantee Kalita	Novartis Healthcare private limited	Non-Govt.	Neurology	2022-2023
9	A Randomized Double Blind Placebo control clinical Study to evaluate the immunodeficiency effect of Swarnprashanin moderately malnourished children	Dr. Vikas Agarwal	Regional Ayurveda Research Institute	Non-Govt.	Clinical Immunology & Rheumatology	2022-2023
<b>2021-2022</b>						
1	A prospective, observational, Single Arm, Multicenter Registry to evaluate clinical outcomes of the shockwave coronary intravascular lithotripsy (IVL) followed by stent implantation in calcified coronary Arteries in Real World Indian Patient population, (Shock India Registry)	Prof. Aditya Kapoor	Trans lumina therapeutics LLP (JSS)	Non-Govt.	Cardiology	2021-2022
2	An Indian Multicentric Phase IV study to assess the safety of crizanlizumab with or without hydroxyurea therapy in sickle cell	Dr. Sanjeev	Novartis Healthcare Pvt.	Non-Govt.	Hem	2021-2022

	disease patients with vaso occlusive crises		Ltd.		at ol og y	
3	A randomized open label, single centre post Market Surveillance Study to evaluate the efficacy and safety of a new antimicrobial wound dressing (VEL VERT) compared to standard dressing (SD) in the treatment of Diabetic foot ulcer	Prof. Gyan Prakash	Datt Mediproducts Pvt. Ltd.	Non-Govt.	En do cri ne Su rg er y	2021-2022
<b>2020-2021</b>						
1	A Randomized Study of Chemotherapy (CT) followed by consolidation CTRT in Locally Advanced Gall Bladder Cancers (LA-GBC) (RACE-GB) Study)	Prof. Sushma Agarwal,	Conquer Cancer, The ASCO Foundation, USA	Non-Govt.	Radiotherapy	2020-2021
2	A Post marketing surveillance (PMS) study for VPRIV® (Velaglycerase Alfa) in India	Prof. Shubha R. Phadke	Shire human genetics Therapies Inc.	Non-Govt.	Medical Genetics	2020-2021

  
**Lt Col Varun Bajpai VSM**  
 Executive Registrar  
 SGPIMS, Lucknow




# Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow

www.spggims.org.in

3	Preventing Adverse Cardiac Events (PACE) in Chronic Obstructive Pulmonary Disease (COPD)	Dr. Alok Nath	George Institute for Global Health	Non-Govt.	Pulmonary Medicine	2020-2021
4	A Randomized, double-blind, Placebo-Controlled, Withdrawl, Safety and Efficiency study of Oral Baricitinib in patients from 1 year to less than 18 years old with systemic Juvenile Idiopathic Arthritis	Dr. Amita Agarwal	Eli Lilly and Company India, Pvt. Ltd.	Non-Govt.	Clinical Immunology & Rheumatology	2020-2021
<b>2019-2020</b>						
1	A Multi-center Randomized Controlled, Phase III study to Evaluate the Clinical Outcomes and Safety of Tocilizumab Along With Standand of Care in Patients with Cytokine Release Syndrome Associated with COVID-19 Infection	Prof. Vikas Agarwal	JSS Medical Research India, Pvt. Ltd., Faridabad	Non-Govt.	Clinical Immunology	2019-2020
2	Multicentric, Phase -IV, Randomized Double blind, placebo-controlled trial Bowel Syndrome in Adults aged 18 years to 65 years	Prof. Uday C. Ghoshal	Medclin Research Pvt. Ltd.	Non-Govt.	Gastroenterology	2019-2020
3	A 12-week phase 3, randomized, double-blind, placebo controlled Adult Chronic	Prof. J. Kalita	Novartis Healthcare Pvt.	Non-Govt.	Neurology	2019-2020

  
**Lt Col Varun Bajpai VSM**  
Executive Registrar  
SGPGIMS, Lucknow

	migrane Patients		Ltd.			
4	A Phase 2 Multicenter, Randomized, Double-blind, Palcebo-controlled, Multiple Dose Proof of concept Study to Evaluate the Efficacy and Safety of Multiple Intravenous Doses of VIS649 in Patients with Immunoglobulin A (IgA) Nephropathy	Prof. Narayan Prasad	George Clinical India Pvt. Ltd.	Non-Govt.	Nephrology	2019-2020
5	A Randomized Double-blind, Multicenter, Palcebo-controlled Phase 3 study with Open-label period to evaluate the efficacy and safty of Inebilizumab in Adults with Myasthebia Gravis	Prof. J. Kalita	Medpace Pvt. Ltd.	Non-Govt.	Neurology	2019-2020
6	A Prospective non-randomized, open label, single-arm, multi-centre, Phase III Clinical study to evaluate efficacy, Pharmacokinetics, and safety of human normal immunoglobulin for intravenous administration in patients with primary immunodeficiency diseases	Prof. Amita Agarwal	Intal Pharmaceutical s Pvt. Ltd.	Non-Govt.	Clinical Immunology and Rheumatology	2019-2020
7	A Phase 3 Randomized open label (Sponsor-blind), active-controlled, parallel group. Multi-center, event driven study innon-dialysis subjects with anemia	Prof. Narayan Prasad	PPD Pharmaceutical development	Non-Govt.	Nephrology	2019-2020




# Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow

www.spgims.org.in

	associated with chronic kidney disease to evaluate the safety and efficacy of Daprodustat compared to darbepoetin alfa		India Pvt. Ltd.			
8	A Phase 3, Randomized, Double blind, Parallel group, Vehicle Controlled Multicentre Study of the Efficacy and safety of GRANEXIN GEL in the treatment of DIABETIC FOOT ULCER (GAIT 1)	Prof. Gyan Chand	JSS Medical Research India Pvt. Ltd.	Non-Govt.	Endocrine Surgery	2019-2020
9	Production of Zirconium-89 and the development of Zr-89 Radiopharmaceuticals	Dr. Manish Dixit	AIEA, Vienna, Austria	Non-Govt, International	Nuclear Medicine	2019-2020
<b>2018-2019</b>						
1	A Prospective, Randomized, Double-blind, Double dummy, Multi Centre, Comparative Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ivabradine Prolonged Release Tablets in Patients with Stable Chronic Heart Failure with Systolic Dysfunction	Prof. Sudeep Kumar	Abbott Healthcare Pvt. Ltd.	Non-Govt.	Cardiology	2018-2019
2	A Prospective, Multicenter, post-marketing surveillance to assess safety & efficacy or	Prof. U. K.	Pharmazz Pvt.	Non-Govt.	Neurology	2018-2019

  
**Lt Col Varun Bajpai VSM**  
Executive Registrar  
SGPGIMS, Lucknow




# Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow

www.spgims.org.in

	perampanel in Indian patients as an adjunctive treatment in partial onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 years or older	Misra	Ltd.			
3	Safety and efficacy of Lipiodol Ultra Fluid in Association with Surgical Glues During Vascular Embolization	Dr. Raghunandan Prasad	Norwich Clinical Service	Non-Govt.	Radiodiagnosis	2018-2019
4	A Prospective, double blind, randomized, placebo controlled Interventional study to evaluate the safety and efficacy of Enzobiotics (Synbiotics and Proteolytic Enzymes) in pre dialysis kidney disease patients	Prof. Anita Saxena	Mylin Biotech India Pvt. Ltd.	Non-Govt.	Nephrology	2018-2019
5	A Prospective Multicenter Post Marketing surveillance to assess safety & efficacy of perampanel in Indian patients as an adjunctive treatment in partial onset seizures with or without secondary generalized seizures in patients with Epilepsy aged 12 years or Older	Prof. U. K. Mishra	Accutest Research Lab. Pvt. Ltd.	Non-Govt.	Neurology	2018-2019
6	A Multicentre, Multiple dose Active controlled....secondary	Prof. Amit	Amgen Technology	Non-Govt.	Nephrology	2018-2019

  
Lt Col Varun Bajpai VSM  
Executive Registrar  
SGPGIMS, Lucknow






# Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow

www.sgpims.org.in

	Hyperparathyroidism	Gupta	Pvt. Ltd.			
7	Pre-Operative Ischemic Evaluation-3 (Poise-3)	Prof. Sanjay Dhiraj	Hamilton Health Sciences Corporation, Canada	Non-Govt.	Anesthesiology	2018-2019
8	A cross-sectional, Multicenter study to determine the Sociodemographic Characteristics, Clinical Profile, and Usage pattern of Antiepileptic Drugs in Persons with Epilepsy in India	Prof. U. K. Mishra / Dr. Jayantee Kalita	Abbott India Ltd.	Non-Govt.	Neurology	2018-2019
9	Flow-Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in subjects with Type 2 diabetes and Chronic Kidney Disease	Prof. Narayan Prasad	Novo Nordisk India Pvt. Ltd., Bangalore	Non-Govt.	Nephrology	2018-2019
10	A Prospective, multi-center, Single-arm clinical study in evaluate safety and performance of the Dafodil pericardial Bioprosthesis in patients who require replacement of their natural or prosthetic arotic or mitral valve	Dr. Nirmal Gupta	Meril life sciences pvt. Ltd.	Non-Govt.	CVTS	2018-2019

  
**Lt Col Varun Bajpai VSM**  
Executive Registrar  
SGPGIMS, Lucknow

11	PARACHUTE: Pazopanib real-world assessment of clinical effectiveness and safety in patients who have undergone treatment in different settings in advanced renal cell carcinoma: A interventional, observational study	Dr. Sanjoy Kumar Sureka	Novartis Healthcare pvt. LTD.	Non-Govt.	Urology and Renal Tranaplantation	2018-2019
12	A Multicentric, Randomized, Double-blind, Placebo Controlled Trial to assess the Efficacy and Safety of Saccharomyces Boulardil CNCM-I 3799 and Bacillus subtilis CU-I combination for treatment of Acute Diarrhea in Indian Children	Dr. Piyali Bhattacharya	Medclin Research Pvt. Ltd.	Non-Govt.	General Hospital	2018-2019
13	A Prospective, Multicentric, Randomized, Double-blind, Placebo controlled phase II Clinical study to compare the safety and efficacy of PMZ 1620 therapy along with standard supportive care in subjects of Mild to moderate Alzheimer Disease	Dr. Jayantee Kalita	Pharmazz	Non-Govt.	Neurology	2018-2019

